Mazdutide 9 mg achieves 81.7% weight reduction ≥5% in Chinese adults with obesity
Background
The global prevalence of obesity continues to rise, posing significant health challenges and increasing the risk of numerous cardiometabolic diseases. Current pharmacotherapies often fall short in achieving substantial and sustained weight loss, or are associated with undesirable side effects. Mazdutide, a dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist, has shown promise in earlier trials at lower doses (4 mg and 6 mg) for weight management. This study specifically investigated the higher 9 mg dose to assess its enhanced efficacy and safety profile in a Chinese adult population with obesity.
Study Design
This randomized, placebo-controlled trial evaluated the efficacy and safety of once-weekly mazdutide 9 mg in Chinese adults with obesity (BMI ≥30 kg/m²). Participants received either mazdutide 9 mg or placebo once weekly via subcutaneous injection for 24 weeks. The primary endpoint was the proportion of participants achieving at least 5% weight reduction from baseline. Secondary endpoints included changes in cardiometabolic risk factors. Safety and tolerability were assessed through monitoring of adverse events.
Results
Once-weekly mazdutide 9 mg demonstrated significant efficacy for weight reduction in Chinese adults with obesity. After 24 weeks of treatment, a remarkable 81.7% of participants receiving mazdutide achieved a weight reduction of at least 5% from baseline. In stark contrast, no participants in the placebo group reached this 5% weight loss threshold. This represents a substantial and statistically significant difference in efficacy. Furthermore, mazdutide treatment was associated with greater improvements in various cardiometabolic risk factors when compared to placebo, although specific numerical improvements were not detailed in the abstract. The most common adverse events were consistent with the known profile of GLP-1 receptor agonists, primarily gastrointestinal in nature.
81.7% of mazdutide-treated participants achieved ≥5% weight reduction, while 0% of placebo participants did.
Key Findings
- Once-weekly mazdutide 9 mg achieved ≥5% weight reduction in 81.7% of participants.
- No participants in the placebo group achieved ≥5% weight reduction.
- Mazdutide treatment led to greater improvements in cardiometabolic risk factors vs. placebo.
- Common adverse events were observed, consistent with GLP-1 receptor agonists.
Why It Matters
This study provides compelling evidence that mazdutide 9 mg is a highly effective option for weight management in Chinese adults with obesity, offering a significant improvement over previous lower doses. For individuals seeking substantial weight loss, this higher dose could represent a new, potent therapeutic strategy. The observed improvements in cardiometabolic risk factors suggest broader health benefits beyond just weight reduction, potentially impacting long-term disease prevention. While specific adverse event rates are not detailed, the mention of 'most common adverse events' implies a known and manageable safety profile. This finding moves mazdutide closer to becoming a widely adopted clinical tool, particularly in populations where obesity is a growing concern, offering a once-weekly protocol that enhances adherence.
mazdutide
obesity
weight-loss
glp-1-agonist
glucagon-agonist
cardiometabolic